Nymox shares slumped nearly 32% in morning trading.
Nymox Pharmaceutical (NASDAQ:NYMX) entered into definitive agreements with institutional and accredited investors for the purchase and sale of ~3M shares at $1.65/share in a registered direct offering for gross proceeds of ~$5M.
NYMX also agreed to issue to the investors, in a concurrent private placement, unregistered warrants to purchase up to ~3M shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments